FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068045682> ?p ?o ?g. }

• W2068045682 endingPage "136" @default.
• W2068045682 startingPage "131" @default.
• W2068045682 abstract "Abstract. In the serum of patients with malignant endocrine gastroenteropancreatic (GEP) tumours, both α-subunit (α-SU), common to all glycoprotein hormones, as well as free β-subunit of human chorionic gonadotropin (hCG-β) have been reported to be elevated in a substantial fraction. Both have been discussed as markers of malignancy in these neoplasms. In the present study we evaluated the diagnostic significance of α-SU and hCG-β as serum markers in patients with malignant endocrine gastroenteropancreatic tumours. The study group consisted of 52 patients with endocrine GEP-malignancies (24 nonfunctioning, 23 carcinoid syndromes, four gastrinoma, one glucagonoma), located in the small intestine (n= 29), pancreas (n= 17), colon or rectum (n= 3), retroperitoneum (n= 2) and stomach (n= 1). α-SU and hCG-β immunoreactivity was also assessed in the serum of patients with benign GEP-tumors (five insulinoma, and three gastrinoma). Concentrations of α-SU and hCG-β were determined using two highly sensitive and specific immunoradiometric assays employing two monoclonal antibodies each. In 19 of 52 patients (37%), either α-SU (n= 9), hCG-β (n= 7) or both subunits (n= 3) were elevated. In the subgroup of 24 patients with nonfunctioning GEP-tumours, increased concentrations of either α-SU (n= 6) or hCG-β (n= 3) or both subunits (n= 1) were found in 10 of 24 patients (42%). In four of 23 patients with carcinoid syndrome (17%), either α-SU (n= 2), hCG-β (n= 1) or both subunits (n= 1) were above the normal range. Of five patients with functionally active endocrine pancreatic islet cell tumours, all had an elevation of at least one of the two substances. In contrast, in the serum of all eight patients with benign GEP-tumours, α-SU and hCG-β were within normal limits. In summary, our data show a high frequency of elevated α-SU or hCG-β immunoreac tivity in the serum of patients with malignant endocrine gastroenteropancreatic tumours. Since immunoreactivity is mostly discordantly elevated, the two markers are well suited to supplement each other. Absolute values had a similar range in the subgroups analysed. The prevalence was highest for functionally active endocrine pancreatic islet cell cancers, but nonfunctioning endocrine GEP-malignancies also exhibited a high frequency of predominantly α-SU immunoreactivity. This is important since this subgroup of endocrine GEP-tumours usually lacks hormonal markers. In patients with carcinoid syndrome, however, increased serum levels of α-SU or hCG-β appear to be rare and of no diagnostic value." @default.
• W2068045682 created "2016-06-24" @default.
• W2068045682 creator A5008355737 @default.
• W2068045682 creator A5018028476 @default.
• W2068045682 creator A5031108452 @default.
• W2068045682 creator A5062021087 @default.
• W2068045682 creator A5074292475 @default.
• W2068045682 creator A5086850031 @default.
• W2068045682 creator A5090646749 @default.
• W2068045682 date "1994-02-01" @default.
• W2068045682 modified "2023-10-18" @default.
• W2068045682 title "Alpha-subunit and human chorionic gonadotropin-β immunoreactivity in patients with malignant endocrine gastroenteropancreatic tumours" @default.
• W2068045682 cites W1989730004 @default.
• W2068045682 cites W1992742983 @default.
• W2068045682 cites W2009125028 @default.
• W2068045682 cites W2013804324 @default.
• W2068045682 cites W2017687261 @default.
• W2068045682 cites W2042030115 @default.
• W2068045682 cites W2043253586 @default.
• W2068045682 cites W2065811361 @default.
• W2068045682 cites W2091877038 @default.
• W2068045682 cites W2111525348 @default.
• W2068045682 cites W2117420485 @default.
• W2068045682 cites W2120040732 @default.
• W2068045682 cites W2163883443 @default.
• W2068045682 cites W2333359998 @default.
• W2068045682 cites W4323875008 @default.
• W2068045682 cites W749347552 @default.
• W2068045682 doi "https://doi.org/10.1111/j.1365-2362.1994.tb00978.x" @default.
• W2068045682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7515807" @default.
• W2068045682 hasPublicationYear "1994" @default.
• W2068045682 type Work @default.
• W2068045682 sameAs 2068045682 @default.
• W2068045682 citedByCount "37" @default.
• W2068045682 countsByYear W20680456822012 @default.
• W2068045682 countsByYear W20680456822015 @default.
• W2068045682 countsByYear W20680456822016 @default.
• W2068045682 crossrefType "journal-article" @default.
• W2068045682 hasAuthorship W2068045682A5008355737 @default.
• W2068045682 hasAuthorship W2068045682A5018028476 @default.
• W2068045682 hasAuthorship W2068045682A5031108452 @default.
• W2068045682 hasAuthorship W2068045682A5062021087 @default.
• W2068045682 hasAuthorship W2068045682A5074292475 @default.
• W2068045682 hasAuthorship W2068045682A5086850031 @default.
• W2068045682 hasAuthorship W2068045682A5090646749 @default.
• W2068045682 hasConcept C104317684 @default.
• W2068045682 hasConcept C126322002 @default.
• W2068045682 hasConcept C134018914 @default.
• W2068045682 hasConcept C176685330 @default.
• W2068045682 hasConcept C2775948956 @default.
• W2068045682 hasConcept C2776986829 @default.
• W2068045682 hasConcept C2777127409 @default.
• W2068045682 hasConcept C2778108375 @default.
• W2068045682 hasConcept C2778563252 @default.
• W2068045682 hasConcept C2778758028 @default.
• W2068045682 hasConcept C2778764654 @default.
• W2068045682 hasConcept C2778782382 @default.
• W2068045682 hasConcept C2779399171 @default.
• W2068045682 hasConcept C2780053029 @default.
• W2068045682 hasConcept C2780103800 @default.
• W2068045682 hasConcept C2781283050 @default.
• W2068045682 hasConcept C46699223 @default.
• W2068045682 hasConcept C49039625 @default.
• W2068045682 hasConcept C55493867 @default.
• W2068045682 hasConcept C71315377 @default.
• W2068045682 hasConcept C71924100 @default.
• W2068045682 hasConcept C86803240 @default.
• W2068045682 hasConceptScore W2068045682C104317684 @default.
• W2068045682 hasConceptScore W2068045682C126322002 @default.
• W2068045682 hasConceptScore W2068045682C134018914 @default.
• W2068045682 hasConceptScore W2068045682C176685330 @default.
• W2068045682 hasConceptScore W2068045682C2775948956 @default.
• W2068045682 hasConceptScore W2068045682C2776986829 @default.
• W2068045682 hasConceptScore W2068045682C2777127409 @default.
• W2068045682 hasConceptScore W2068045682C2778108375 @default.
• W2068045682 hasConceptScore W2068045682C2778563252 @default.
• W2068045682 hasConceptScore W2068045682C2778758028 @default.
• W2068045682 hasConceptScore W2068045682C2778764654 @default.
• W2068045682 hasConceptScore W2068045682C2778782382 @default.
• W2068045682 hasConceptScore W2068045682C2779399171 @default.
• W2068045682 hasConceptScore W2068045682C2780053029 @default.
• W2068045682 hasConceptScore W2068045682C2780103800 @default.
• W2068045682 hasConceptScore W2068045682C2781283050 @default.
• W2068045682 hasConceptScore W2068045682C46699223 @default.
• W2068045682 hasConceptScore W2068045682C49039625 @default.
• W2068045682 hasConceptScore W2068045682C55493867 @default.
• W2068045682 hasConceptScore W2068045682C71315377 @default.
• W2068045682 hasConceptScore W2068045682C71924100 @default.
• W2068045682 hasConceptScore W2068045682C86803240 @default.
• W2068045682 hasIssue "2" @default.
• W2068045682 hasLocation W20680456821 @default.
• W2068045682 hasLocation W20680456822 @default.
• W2068045682 hasOpenAccess W2068045682 @default.
• W2068045682 hasPrimaryLocation W20680456821 @default.
• W2068045682 hasRelatedWork W1497550712 @default.
• W2068045682 hasRelatedWork W1575719962 @default.
• W2068045682 hasRelatedWork W2081962584 @default.
• W2068045682 hasRelatedWork W2093487257 @default.

• next